cific cuts in two different DNA sites to eliminate the genetic mutation causing the disease. This isn't the first gene editing technique to emerge; Sangamo Biosciences (NASDAQ: SGMO) and its zinc finger nuclease platform have the most advanced gene editing candidate, a potential therapy for HIV in Phase 2 testing.

teinueey " Cc: Dubov, Anastasia X From: Barrett, Paul S Sent: Tue 5/28/2013 1:49:48 PM Subject: RE: Well received. Will buy 50,000 of SGMO (Sangamo Biosciences). Spend around $413K. Paul Paul Barrett I Managing Director I Global Investment Opportunities Group 13.P. Morgan Private Bank I New York, NY MI T

rrett, Paul Sent: Tuesday, May 28, 2013 9:50 AM To: Jeffrey Epstein Cc: Dubov, Anastasia X Subject: RE: Well received. Will buy 50,000 of SGMO (Sangamo Biosciences). Spend around $413K. Paul Paul Barrett I Managing Director I Global Investment Opportunities Group I IP. Morgan Private Bank I 320 Park Avenue, 1

S Sent: Tu=sday, May 28, 2013 9:50 AM To: Jeffrey Epstein Dubov, Anastasia X Subject: RE: =/p> <=p> Well received=2E Will buy 50,000 of SGMO (Sangamo Biosciences). Spend a=ound $413K. Paul=/o:p> =div style="border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt =in Din 0in"> From:=span style="font-size:10